Jacobson TA - Search Results

1

Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.

Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif JC, Ballantyne CM; REDUCE-IT Investigators. Bhatt DL, et al. Among authors: jacobson ta. N Engl J Med. 2019 Jan 3;380(1):11-22. doi: 10.1056/NEJMoa1812792. Epub 2018 Nov 10. N Engl J Med. 2019. PMID: 30415628 Clinical Trial.

2

Maximizing the cost-effectiveness of lipid-lowering therapy.

Jacobson TA, Schein JR, Williamson A, Ballantyne CM. Jacobson TA, et al. Arch Intern Med. 1998 Oct 12;158(18):1977-89. doi: 10.1001/archinte.158.18.1977. Arch Intern Med. 1998. PMID: 9778197 Review.

3

Impact of evidence-based "clinical judgment" on the number of American adults requiring lipid-lowering therapy based on updated NHANES III data. National Health and Nutrition Examination Survey.

Jacobson TA, Griffiths GG, Varas C, Gause D, Sung JC, Ballantyne CM. Jacobson TA, et al. Arch Intern Med. 2000 May 8;160(9):1361-9. doi: 10.1001/archinte.160.9.1361. Arch Intern Med. 2000. PMID: 10809042

4

Characteristics of US adults with the metabolic syndrome and therapeutic implications.

Jacobson TA, Case CC, Roberts S, Buckley A, Murtaugh KM, Sung JC, Gause D, Varas C, Ballantyne CM. Jacobson TA, et al. Diabetes Obes Metab. 2004 Sep;6(5):353-62. doi: 10.1111/j.1462-8902.2004.00354.x. Diabetes Obes Metab. 2004. PMID: 15287928

5

Hypertriglyceridemia and cardiovascular risk reduction.

Jacobson TA, Miller M, Schaefer EJ. Jacobson TA, et al. Clin Ther. 2007 May;29(5):763-777. doi: 10.1016/j.clinthera.2007.05.002. Clin Ther. 2007. PMID: 17697898 Review.

6

Role of n-3 fatty acids in the treatment of hypertriglyceridemia and cardiovascular disease.

Jacobson TA. Jacobson TA. Am J Clin Nutr. 2008 Jun;87(6):1981S-90S. doi: 10.1093/ajcn/87.6.1981S. Am J Clin Nutr. 2008. PMID: 18541599 Free article.

7

Comparison of cardiovascular event rates in patients without cardiovascular disease in whom atorvastatin or simvastatin was newly initiated.

Jacobson TA, Wertz DA, Hoy T, Kuznik A, Grochulski D, Cziraky M. Jacobson TA, et al. Mayo Clin Proc. 2008 Dec;83(12):1316-25. doi: 10.1016/S0025-6196(11)60779-9. Mayo Clin Proc. 2008. PMID: 19046550

8

Chronic kidney disease and statins: improving cardiovascular outcomes.

Walker DB, Walker TJ, Jacobson TA. Walker DB, et al. Among authors: jacobson ta. Curr Atheroscler Rep. 2009 Jul;11(4):301-8. doi: 10.1007/s11883-009-0046-2. Curr Atheroscler Rep. 2009. PMID: 19500494 Review.

9

The importance of non-HDL cholesterol reporting in lipid management.

Blaha MJ, Blumenthal RS, Brinton EA, Jacobson TA; National Lipid Association Taskforce on Non-HDL Cholesterol. Blaha MJ, et al. Among authors: jacobson ta. J Clin Lipidol. 2008 Aug;2(4):267-73. doi: 10.1016/j.jacl.2008.06.013. Epub 2008 Jun 28. J Clin Lipidol. 2008. PMID: 21291742

10

Opening a new lipid "apo-thecary": incorporating apolipoproteins as potential risk factors and treatment targets to reduce cardiovascular risk.

Jacobson TA. Jacobson TA. Mayo Clin Proc. 2011 Aug;86(8):762-80. doi: 10.4065/mcp.2011.0128. Mayo Clin Proc. 2011. PMID: 21803958 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

208 results

Search Page